Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis

被引:39
作者
Harbarth, S [1 ]
Garbino, J
Pugin, J
Romand, JA
Pittet, D
机构
[1] Univ Hosp Geneva, Div Infect Dis, Geneva, Switzerland
[2] Univ Hosp Geneva, Div Med & Surg Intens Care, Geneva, Switzerland
关键词
D O I
10.1007/s10096-005-0018-6
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In order to determine whether combination antibiotic therapy decreases mortality after severe pneumococcal infection, a retrospective study of a cohort of 1,840 adult patients with severe sepsis or septic shock enrolled in two multicenter clinical trials between 1994 and 1999 was conducted. Among 107 patients with monobacterial pneumococcal sepsis, the case-fatality rate was 20% (five of 25) for patients who received antibiotic monotherapy compared with 19.5% (16 of 82) for patients who received combination therapy (adjusted hazard ratio, 1.1; 95% CI, 0.4-3.1). Similarly, monotherapy did not increase the risk of death (adjusted hazard ratio, 1.0; 95% CI, 0.2-4.8) among bacteremic patients (n=75). However, the latter analysis may have been underpowered (power, 58%) to detect a difference in mortality. Overall, in contrast to recently published reports, these results suggest that combination antibiotic therapy does not decrease mortality after severe pneumococcal sepsis.
引用
收藏
页码:688 / 690
页数:3
相关论文
共 9 条
[1]   p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock - A randomized controlled multicenter trial [J].
Abraham, E ;
Glauser, MP ;
Butler, T ;
Garbino, J ;
Gelmont, D ;
Laterre, PF ;
Kudsk, K ;
Bruining, HA ;
Otto, C ;
Tobin, E ;
Zwingelstein, C ;
Lesslauer, W ;
Leighton, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (19) :1531-1538
[2]   Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients [J].
Abraham, E ;
Laterre, PF ;
Garbino, J ;
Pingleton, S ;
Butler, T ;
Dugernier, T ;
Margolis, B ;
Kudsk, K ;
Zimmerli, W ;
Anderson, P ;
Reynaert, M ;
Lew, D ;
Lesslauer, W ;
Passe, S ;
Cooper, P ;
Burdeska, A ;
Modi, M ;
Leighton, A ;
Salgo, M ;
Van der Auwera, P .
CRITICAL CARE MEDICINE, 2001, 29 (03) :503-510
[3]   Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia [J].
Baddour, LM ;
Yu, VL ;
Klugman, KP ;
Feldman, C ;
Ortqvist, A ;
Rello, J ;
Morris, AJ ;
Luna, CM ;
Snydman, DR ;
Ko, WC ;
Chedid, MBF ;
Hui, DS ;
Andremont, A ;
Chiou, CCC .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (04) :440-444
[4]   Microbiologic findings and correlations with serum tumor necrosis factor-α in patients with severe sepsis and septic shock [J].
Cohen, J ;
Abraham, E .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (01) :116-121
[5]  
File TM, 2003, CLIN INFECT DIS, V36, P396, DOI 10.1086/367545
[6]   Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis [J].
Harbarth, S ;
Garbino, J ;
Pugin, J ;
Romand, JA ;
Lew, D ;
Pittet, D .
AMERICAN JOURNAL OF MEDICINE, 2003, 115 (07) :529-535
[7]   Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia [J].
Martínez, JA ;
Horcajada, JP ;
Almela, M ;
Marco, F ;
Soriano, A ;
García, E ;
Marco, MA ;
Torres, A ;
Mensa, J .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (04) :389-395
[8]   Clinical use of ceftriaxone - A pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding [J].
Perry, TR ;
Schentag, JJ .
CLINICAL PHARMACOKINETICS, 2001, 40 (09) :685-694
[9]   Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia [J].
Waterer, GW ;
Somes, GW ;
Wunderink, RG .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (15) :1837-1842